Dexter Yan
Senior Reporter
![](/-/media/staff-photos/dexter-yan-round.png?rev=11d3c6fbc3034dd6931360182bf3e1aa)
Dexter Yan is a senior writer covering China’s surging pharma industry on the APAC Pharma news team. With a keen interest in R&D and commercial activities taking place around the clock, he is always on the lookout for opportunities to keep readers better informed of any developments in the field.
Latest From Dexter Yan
Asia Deal Watch: Orum, Vertex Team Up On Gene Editing Conditioning Agents
Plus deals involving Eisai/Sato, Keymed/Belenos, Taiho/Arcus, IASO/Innovent, Biocytogen/SOTIO, Ensol/Spine, TMS/Hokkaido University and Yuhan/Ubix.
China’s Public Payer Challenged To Support Domestic Innovative Drug Market
One Chinese biotech executive is entertaining hopes of China’s domestic market for novel drugs growing to CNY300bn ($41bn). However, the country’s public payer spent just CNY90bn on such products in 2023 and is expected to increase expenditure to more than CNY100bn this year.
HUTCHMED Switches Clinical Strategy To Rely On Partnerships For Late-Stage Assets In US
Having initiated China-only Phase III trials with three oncology and autoimmune drug candidates, HUTCHMED is looking for partnerships to take the molecules to the clinic in the US.
Chinese Biotech Funding Rebounds As $100m VC/PE Deals Return
AI specialist METiS Pharmaceuticals raked in $100m in a series C round, while four other deals backed by venture capital and private equity firms crossed the CNY100m ($14m) mark in the latest fundraisings by Chinese biopharma companies.
Chinese Public Healthcare Insurance Official Defends Steep Drug Price Cuts
China’s National Healthcare Security Administration (NHSA) seems determined to require pharma firms to comply with the agency’s request to cap the prices of innovative drugs, according to a senior official directly involved in annual price negotiations.
ADA: Hengrui, Innovent’s Incretins Shine In China Obesity Studies
Positive clinical outcomes for Hengrui and Innovent/Lilly’s obesity candidates presented at ADA were based on trials that enrolled Chinese subjects and were characterized by fewer women and less severe obesity than similar Western studies. Even so, some of the data appear to stack up well against western rival drugs.